Journal of Medical Genetics 2009;46:689-693
LETTERS TO JMG
High frequency of de novo mutations in Li–Fraumeni syndrome
1 MEDomics, Azusa, California, USA
2 Department of Molecular Genetics, City of Hope, Duarte, California, USA
3 Bioinformatics Group, Department of Molecular Diagnosis, City of Hope, Duarte, California, USA
4 Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Correspondence to Dr S S Sommer, MEDomics, LLC, 426 N. San Gabriel Ave, Azusa, CA 91702, USA; ssommer{at}medomics.com
Background: Li–Fraumeni syndrome is an autosomal dominant cancer predisposition syndrome caused by germline mutations in the TP53 gene. The frequency of germline de novo TP53 mutations is largely unknown; few unequivocal de novo mutations have been reported.
Methods and results: Of 341 patients with early onset cancer sent for clinical testing to a national reference laboratory, 75 patients had TP53 germline mutations. Five (7%) de novo mutations were identified, as well as an additional 10 TP53 germline mutations likely to be de novo by family history. The frequency of de novo TP53 mutations in this patient sample is at least 7% and may be as high as 20%.
Conclusions: The possibility that de novo germline TP53 mutations are relatively common has implications for testing and the identification of potential Li–Fraumeni syndrome in patients with little or no family history of cancer.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
